bivalent=True/ administration_date=30Sep2023; Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old male patient received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 30Sep2023 at 11:00 as dose 1, single (Lot number: MF9572) at the age of 63 years, in left arm for covid-19 immunisation. The patient didn't receive bnt162b2 omi xbb.1.5 (BNT162B2 OMI XBB.1.5). The patient's relevant medical history included: "CTCL" (unspecified if ongoing); "Known allergies: PCN" (unspecified if ongoing); "Known allergies: bee venom" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: bnt162b2 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, is bivalent: True, prev dose lot number: 33130BA, prev dose lot unknown: False, prev dose administration date: 31Mar2022,, prev dose dose number: 4), administration date: 31Mar2022, when the patient was 61-year-old, for COVID-19 immunization, reaction(s): "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose"; bnt162b2 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, is bivalent: True, prev dose lot number: FF2590, prev dose lot unknown: False, prev dose administration date: 13Oct2021,, prev dose dose number: 3), administration date: 13Oct2021, when the patient was 61-year-old, for Covid-19 immunization, reaction(s): "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose"; bnt162b2 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, is bivalent: False, prev dose lot number: EP6955, prev dose lot unknown: False, prev dose administration date: 25Mar2021,, prev dose dose number: 2), administration date: 25Mar2021, when the patient was 60-year-old, for Covid-19 immunization, reaction(s): "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose"; bnt162b2 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, is bivalent: False, prev dose lot number: EN6198, prev dose lot unknown: False, prev dose administration date: 04Mar2021,, prev dose dose number: 1), administration date: 04Mar2021, when the patient was 60-year-old, for Covid-19 immunization, reaction(s): "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose"; bnt162b2;bnt162b2 omi ba.4-5 (prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, is bivalent: False, prev dose lot number: GH9693, prev dose lot unknown: False, prev dose administration date: 06Oct2022,, prev dose dose number: 6), administration date: 06Oct2022, when the patient was 62-year-old, for Covid-19 immunization, reaction(s): "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose"; Bnt162b2 ({prev dose product: COVID 19, prev dose brand: Pfizer, prev dose brand unknown: False, is bivalent: False, prev dose lot unknown: True, prev dose lot unknown reason: Not available/provided to reporter at the time of report completion, prev dose dose number: 5), for Covid-19 immunization, reaction(s): "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose". The following information was reported: TINNITUS (non-serious) with onset 2023, outcome "not recovered", described as "Experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose"; WRONG PRODUCT ADMINISTERED (non-serious) with onset 30Sep2023 at 11:00, outcome "unknown", described as "bivalent=True/ administration_date=30Sep2023". The events "experienced bilateral, persistent tinnitus soon after receiving first dose, and worsens with each subsequent dose" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of tinnitus. Additional information: Patient was evaluated by ENT and audiologist at (Withheld). MRI ordered, no causes identified.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.